Global Circular RNA Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Circular RNA Therapeutics Market Size

• The global Circular RNA Therapeutics market size was valued at USD 784 Million in 2025and is expected to reach USD 4188.13 Million by 2033, at a CAGR of 23.30% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress within RNA biology and circular RNA engineering platforms, leading to increased clinical translation of circRNA-based therapeutics for oncology, rare disease, and vaccine applications
• Furthermore, rising demand for stable, immunologically favorable, and highly customizable RNA therapeutic modalities is establishing circular RNA as the next-generation evolution in the RNA therapeutics landscape beyond conventional mRNA. These converging factors are accelerating the uptake of Circular RNA Therapeutics solutions, thereby significantly boosting the industry's growth

Circular RNA Therapeutics Market Analysis

• Circular RNA (circRNA) therapeutics, offering a novel RNA-based treatment modality characterized by a covalently closed loop structure that confers exceptional resistance to exonuclease degradation and enables prolonged protein expression compared to conventional linear mRNA, are increasingly vital components of the emerging precision RNA medicine landscape
• The escalating demand for circular RNA therapeutics is primarily fueled by the extraordinary durability advantages of circRNA over linear mRNA demonstrated in preclinical and early clinical studies, the expanding RNA engineering toolkit enabling sophisticated circular RNA design and optimization, and growing pharmaceutical industry investment in next-generation RNA therapeutic platforms
• North America dominated the circular RNA therapeutics market with the largest revenue share of 46.20% in 2025, characterized by the highest concentration of circRNA platform companies, leading academic research institutions driving foundational circRNA biology discovery, and strong venture capital investment in RNA technology biotechnology companies
• Asia-Pacific is expected to be the fastest growing region in the circular RNA therapeutics market during the forecast period due to substantial government investment in mRNA and RNA therapeutics infrastructure following the COVID-19 pandemic, rapidly expanding RNA manufacturing capabilities, and increasing academic and industrial circRNA research activity in China, Japan, and South Korea
• The In Vitro Transcription segment held the largest market revenue share of 52.6% in 2025, driven by its widespread use in scalable and efficient circular RNA production

Report Scope and Circular RNA Therapeutics Market Segmentation

Circular RNA Therapeutics Market Trends

“Circular RNA Vaccine Platforms Emerging as Next-Generation Immunization Technology”

• A significant and accelerating trend in the global Circular RNA Therapeutics market is the rapid development and early clinical evaluation of circular RNA-based vaccine platforms that leverage the unique structural advantages of circRNA to generate sustained, high-magnitude immune responses with potentially superior durability compared to conventional linear mRNA vaccines. This emerging application area is receiving extraordinary scientific and commercial attention following the extraordinary success of mRNA vaccine technology demonstrated during the COVID-19 pandemic
• For Instance, Orna Therapeutics has advanced its proprietary oRNA platform into preclinical studies evaluating circular RNA cancer vaccines encoding multiple tumor-associated antigens, demonstrating superior antigen expression duration of up to 10-fold longer compared to equivalent linear mRNA constructs and significantly enhanced cytotoxic T-cell responses in murine tumor models
• Circular RNA vaccine platforms enable features such as prolonged antigen presentation through sustained protein expression from highly stable circRNA constructs, reduced innate immune stimulation compared to unmodified linear mRNA, and the potential for dose-sparing through enhanced immunogenicity per mRNA molecule delivered. These properties have demonstrated vaccine response durability advantages of 48% to 76% in preclinical immunogenicity comparisons with leading mRNA vaccine platforms
• The seamless integration of circular RNA vaccine development platforms with established LNP (lipid nanoparticle) delivery technologies developed for the linear mRNA vaccine field facilitates rapid translation of circRNA vaccine candidates from discovery through clinical development. Leading circRNA platform companies are actively co-developing specialized LNP formulations optimized for circRNA physicochemical properties
• This trend towards circular RNA vaccine development is creating substantial new market opportunities across infectious disease prevention, cancer immunotherapy, and personalized neoantigen vaccine applications that collectively represent a multibillion-dollar addressable market over the forecast period
• The demand for circular RNA vaccine platforms is attracting unprecedented venture capital investment and Big Pharma licensing interest, driving rapid expansion of the circRNA therapeutics pipeline and commercial landscape

Circular RNA Therapeutics Market Dynamics

Driver

“Growing Need Due to Superior Stability and Emerging Clinical Validation of circRNA”

• The demonstrated superiority of circular RNA's stability and durability profile over conventional linear mRNA, with circRNA constructs exhibiting resistance to rapid 5'-to-3' exonuclease degradation and half-lives of 5 to 7 days compared to hours for unmodified linear mRNA, is a significant fundamental driver for the growing pharmaceutical interest and research investment in circular RNA therapeutic platforms
• For Instance, in March 2025, Laronde announced the IND filing for its first-ever circular RNA therapeutic candidate LRD-001, a circRNA encoding erythropoietin for the treatment of anemia in chronic kidney disease, marking a landmark milestone as one of the first circRNA therapeutics to enter formal regulatory clinical development in the United States. Such milestones by emerging companies are expected to drive the Circular RNA Therapeutics industry growth in the forecast period
• As pharmaceutical companies and biotechnology investors become increasingly aware of the differentiated durability, immunogenicity, and production scalability advantages of circular RNA over conventional linear mRNA therapeutics, circRNA platforms are attracting substantial early-stage research investment, strategic licensing deals, and platform development partnerships
• Furthermore, the rapid accumulation of foundational circular RNA biology knowledge, driven by thousands of peer-reviewed publications annually and significant academic research investment globally, is accelerating the translation of circRNA biological insights into actionable therapeutic engineering strategies and validated clinical candidates
• The strong intellectual property landscape surrounding novel circular RNA production methods, engineering optimization strategies, and delivery platform innovations is in addition providing substantial competitive differentiation and commercial protection for leading circRNA platform companies, driving continued proprietary technology investment

Restraint/Challenge

“Circular RNA Production Complexity and Delivery Platform Optimization Challenges”

• The significant technical complexity of producing high-purity, biologically functional circular RNA at commercial scale, including the challenges of efficient RNA circularization, removal of linear RNA contaminants, and maintenance of correct secondary structure, poses a substantial manufacturing development challenge that represents a major near-term constraint on clinical translation timelines for circRNA therapeutics
• For Instance, current state-of-the-art circular RNA production yields using Group I or Group II intron-mediated autocatalytic splicing methods typically achieve circularization efficiencies of 30% to 70%, requiring extensive downstream purification to remove immunogenic linear RNA by-products that could confound clinical tolerability assessment and compromise therapeutic safety profiles
• Addressing these manufacturing challenges through the development of improved circularization chemistry, novel enzymatic ligation strategies, and scalable purification processes is a critical area of technology investment for leading circRNA platform companies. Companies such as Orna Therapeutics and Laronde are investing heavily in proprietary manufacturing process development to establish commercially viable, GMP-compliant circRNA production platforms capable of supporting late-stage clinical development and eventual commercial launch
• In addition, the need to develop circRNA delivery systems with optimized tissue tropism, cellular uptake efficiency, and endosomal escape capabilities — particularly for therapeutic applications requiring efficient delivery to specific cell types beyond hepatocytes — represents a significant formulation development challenge that requires substantial investment in novel lipid nanoparticle and non-viral delivery technologies
• Overcoming these manufacturing and delivery challenges through sustained technology development investment, strategic industry-academic collaborations, and regulatory science advances in RNA therapeutic characterization will be vital for sustained market growth

Circular RNA Therapeutics Market Scope

The market is segmented on the basis of application, technology, and end user.

• By Application

On the basis of application, the Circular RNA Therapeutics market is segmented into Oncology, Rare Diseases, Infectious Diseases, Neurological Disorders, and Others. The Oncology segment dominated the largest market revenue share of 46.8% in 2025, driven by the strong potential of circular RNA-based therapies in cancer immunotherapy, tumor suppression, and gene regulation mechanisms. Increasing global cancer burden and demand for next-generation precision oncology solutions are key growth drivers. High stability and long-lasting expression of circular RNA molecules make them highly suitable for cancer-targeted therapies. Rising investment in RNA-based drug development pipelines is further strengthening segment dominance. Expanding clinical trials focused on tumor-specific RNA therapeutics is accelerating adoption. Pharmaceutical companies are prioritizing oncology applications due to high unmet medical need. Advancements in mRNA and RNA delivery platforms are also supporting growth. Overall, oncology remains the primary application due to strong clinical and commercial potential.

The Neurological Disorders segment is expected to witness the fastest CAGR of 24.3% from 2026 to 2033, driven by increasing research into RNA-based treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. Circular RNA’s ability to provide stable and long-term gene expression is highly advantageous for central nervous system targeting. Rising prevalence of neurological disorders globally is increasing demand for novel therapeutic approaches. Limited efficacy of conventional therapies is pushing adoption of advanced RNA-based solutions. Growing investments in brain-targeted drug delivery technologies are supporting expansion. Academic and biotech collaborations are accelerating innovation in this segment. Increasing funding from government and research organizations is boosting development pipelines. Overall, neurological disorders represent a high-growth emerging application area.

• By Technology

On the basis of technology, the market is segmented into In Vitro Transcription, Chemical Synthesis, and Cellular Engineering. The In Vitro Transcription segment held the largest market revenue share of 52.6% in 2025, driven by its widespread use in scalable and efficient circular RNA production. This method enables high-yield synthesis with controlled quality, making it the preferred approach for preclinical and clinical research. Increasing demand for rapid and cost-effective RNA manufacturing is supporting segment leadership. Strong adoption in pharmaceutical R&D pipelines is further enhancing growth. Technological advancements in enzymatic circularization are improving production efficiency. Expanding use in therapeutic-grade RNA development is boosting commercialization potential. Established infrastructure and standardized protocols contribute to dominance. Overall, in vitro transcription remains the backbone of circular RNA production.

The Cellular Engineering segment is anticipated to witness the fastest CAGR of 25.7% from 2026 to 2033, driven by advancements in synthetic biology and engineered cell systems for in vivo RNA production. This approach enables sustained and localized therapeutic RNA expression, improving treatment outcomes. Rising interest in personalized medicine and cell-based therapies is fueling adoption. Increasing investments in gene editing and CRISPR-based technologies are supporting growth. Academic and biotech collaborations are accelerating innovation in engineered cellular platforms. The potential for long-term therapeutic effects is attracting strong research interest. Expanding applications in regenerative medicine are further boosting demand. Overall, cellular engineering is emerging as a high-growth next-generation technology segment.

• By End User

On the basis of end user, the market is segmented into Pharmaceutical Companies, Biotech Startups, Academic Research, and Others. The Pharmaceutical Companies segment accounted for the largest market revenue share of 49.1% in 2025, driven by strong investments in RNA-based drug discovery and large-scale clinical development capabilities. These companies have robust funding and infrastructure to advance circular RNA therapeutics from research to commercialization. Increasing focus on precision medicine and biologics development is supporting dominance. Strategic partnerships with biotech firms and academic institutions are enhancing innovation pipelines. Strong regulatory expertise and global distribution networks further strengthen their leadership position. Rising demand for next-generation biologics is accelerating adoption. Continuous R&D spending in oncology and rare diseases is boosting segment growth. Overall, pharmaceutical companies remain the key commercial drivers.

The Biotech Startups segment is expected to witness the fastest CAGR of 27.5% from 2026 to 2033, driven by increasing innovation in RNA therapeutics and strong venture capital funding. Startups are playing a crucial role in developing novel circular RNA platforms and delivery systems. Growing ecosystem support from incubators and research hubs is accelerating product development. Flexible research structures allow faster innovation cycles compared to large companies. Strategic collaborations with pharmaceutical firms are supporting commercialization pathways. Rising interest in personalized and precision medicine is fueling startup activity. Expanding pipeline of early-stage RNA therapeutics is boosting growth potential. Overall, biotech startups are emerging as key innovation drivers in this market.

Circular RNA Therapeutics Market Regional Analysis

• North America dominated the Circular RNA Therapeutics market with the largest revenue share of 46.20% in 2025, driven by a strong concentration of circular RNA (circRNA) platform companies, leading academic research institutions advancing foundational circRNA biology, and significant venture capital investment in RNA-based biotechnology firms. The region also benefits from a mature innovation ecosystem that accelerates translational research and commercialization of next-generation RNA therapeutics
• Researchers and biotech companies in the region are increasingly focused on leveraging circRNA’s enhanced stability and translational efficiency for therapeutic applications, particularly in oncology, infectious diseases, and rare genetic disorders. Strong collaboration between academia, biotech startups, and pharmaceutical companies is further accelerating pipeline development and clinical translation
• This widespread leadership is further supported by advanced biotechnology infrastructure, robust funding ecosystems, and early adoption of RNA therapeutic platforms, establishing North America as a global hub for Circular RNA Therapeutics innovation

U.S. Circular RNA Therapeutics Market Insight

The U.S. circular RNA therapeutics market captured the largest revenue share in 2025 within North America, driven by rapid expansion of RNA-focused biotechnology companies and strong academic research output in circRNA science. The country has become a central hub for innovation in RNA therapeutics, with increasing investments in platform technologies and next-generation gene regulation approaches. Growing collaboration between universities, biotech firms, and pharmaceutical companies is accelerating discovery and clinical translation of circular RNA-based therapies. In addition, strong venture capital funding and supportive regulatory pathways are enabling faster development of experimental RNA therapeutics.

Europe Circular RNA Therapeutics Market Insight

The Europe circular RNA therapeutics market is projected to expand at a substantial CAGR throughout the forecast period, driven by increasing investment in RNA-based drug discovery, strong academic research networks, and growing interest in next-generation gene therapies. The region is witnessing rising collaboration between universities and biotech companies focused on RNA innovation. European research institutions are actively contributing to circRNA biology and therapeutic applications, particularly in oncology and rare disease treatment. Supportive public funding programs and expanding biotechnology ecosystems are further strengthening market growth across major countries.

U.K. Circular RNA Therapeutics Market Insight

The U.K. circular RNA therapeutics market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by strong academic leadership in RNA biology and increasing investment in advanced therapeutics research. The country’s well-established life sciences sector is actively contributing to RNA innovation. Growing partnerships between universities, biotech startups, and pharmaceutical companies are accelerating development of circular RNA platforms. In addition, strong government support for genomic medicine and biotechnology research is further enhancing market expansion.

Germany Circular RNA Therapeutics Market Insight

The Germany circular RNA therapeutics market is expected to expand at a considerable CAGR during the forecast period, fueled by strong biotechnology infrastructure, increasing investment in RNA research, and a growing focus on precision medicine. The country is actively supporting innovation in advanced therapeutic modalities. German research institutions and biotech companies are increasingly exploring circular RNA applications in drug development, particularly in oncology and genetic disorders. Strong funding mechanisms and collaboration between academia and industry are further driving market growth.

Asia-Pacific Circular RNA Therapeutics Market Insight

The Asia-Pacific circular RNA therapeutics market is poised to grow at the fastest CAGR during the forecast period, driven by substantial government investment in RNA therapeutics infrastructure following the COVID-19 pandemic, expanding RNA manufacturing capabilities, and increasing research activity in circular RNA technologies. The region is rapidly strengthening its biotechnology ecosystem. Countries such as China, Japan, and South Korea are significantly expanding academic and industrial research in RNA-based therapeutics. Rising collaboration between research institutions and biotech companies, along with increasing funding for advanced biologics, is accelerating regional market development.

Japan Circular RNA Therapeutics Market Insight

The Japan circular RNA therapeutics market is gaining momentum due to strong biomedical research capabilities, advanced biotechnology infrastructure, and increasing focus on next-generation RNA therapeutics. The country’s aging population is further driving demand for innovative treatment approaches. Japan is witnessing growing research activity in circular RNA applications, supported by collaboration between universities, research institutes, and biotech firms. Strong emphasis on precision medicine and regenerative therapeutics is further contributing to market expansion.

China Circular RNA Therapeutics Market Insight

The China circular RNA therapeutics market accounted for the largest market revenue share in Asia Pacific in 2025, driven by expanding government investment in RNA-based biotechnology, rapid growth of domestic biotech companies, and increasing academic research in circular RNA biology. The country is becoming a key hub for RNA innovation. China is also experiencing strong growth in RNA manufacturing capacity and translational research programs. Expanding collaboration between research institutions and biotechnology firms, along with supportive national innovation policies, is further strengthening market development.

Circular RNA Therapeutics Market Share

The Circular RNA Therapeutics industry is primarily led by well-established companies, including:

• Moderna (U.S.)
• BioNTech (Germany)
• Pfizer (U.S.)
• Roche (Switzerland)
• Novartis (Switzerland)
• AstraZeneca (U.K.)
• Sanofi (France)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Amgen (U.S.)
• Regeneron Pharmaceuticals (U.S.)
• Takeda Pharmaceutical (Japan)
• GSK (U.K.)
• Daiichi Sankyo (Japan)
• CureVac (Germany)
• Arcturus Therapeutics (U.S.)
• Ethris (Germany)
• Strand Therapeutics (U.S.)
• Orna Therapeutics (U.S.)
• Circio Holding (Norway)

Latest Developments in Global Circular RNA Therapeutics Market

• In March 2025, Laronde announced the filing of an Investigational New Drug (IND) application with the U.S. FDA for LRD-001, its lead circular RNA therapeutic encoding erythropoietin for anemia in chronic kidney disease, representing one of the first circRNA therapeutic candidates to enter formal clinical regulatory development in the United States
• In January 2025, Orna Therapeutics published landmark preclinical data in Nature Biotechnology demonstrating that its oRNA circular RNA cancer vaccine platform achieved complete tumor regression in 78% of treated mice in aggressive melanoma and colorectal cancer models, with response durability sustained beyond 90 days, substantially exceeding comparable linear mRNA vaccine benchmarks
• In November 2024, CirCode, a leading Chinese circRNA therapeutics company, announced the completion of a USD 120 million Series B financing round co-led by major Chinese and international biotechnology investors, reflecting the rapid growth of global interest in circular RNA therapeutics development and the emergence of China as a significant center of circRNA innovation
• In August 2024, Circular Genomics announced a strategic research collaboration with Pfizer to co-develop circular RNA-based neurological disorder therapeutics targeting treatment-resistant depression and other CNS conditions, representing a major endorsement of circRNA therapeutic platform potential by a leading global pharmaceutical company
• In April 2024, Therorna reported positive preclinical results for its proprietary self-amplifying circular RNA (saRNA) platform demonstrating substantially enhanced protein expression levels compared to first-generation circRNA constructs while maintaining the superior stability and low immunogenicity profile characteristic of circular RNA architecture

SKU-75750